These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

282 related items for PubMed ID: 25249652

  • 1. Weight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release.
    Garvey WT, Ryan DH, Bohannon NJ, Kushner RF, Rueger M, Dvorak RV, Troupin B.
    Diabetes Care; 2014 Dec; 37(12):3309-16. PubMed ID: 25249652
    [Abstract] [Full Text] [Related]

  • 2. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study.
    Garvey WT, Ryan DH, Look M, Gadde KM, Allison DB, Peterson CA, Schwiers M, Day WW, Bowden CH.
    Am J Clin Nutr; 2012 Feb; 95(2):297-308. PubMed ID: 22158731
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of phentermine and topiramate versus phentermine/topiramate extended-release in obese adults.
    Aronne LJ, Wadden TA, Peterson C, Winslow D, Odeh S, Gadde KM.
    Obesity (Silver Spring); 2013 Nov; 21(11):2163-71. PubMed ID: 24136928
    [Abstract] [Full Text] [Related]

  • 4. Prevention of type 2 diabetes in subjects with prediabetes and metabolic syndrome treated with phentermine and topiramate extended release.
    Garvey WT, Ryan DH, Henry R, Bohannon NJ, Toplak H, Schwiers M, Troupin B, Day WW.
    Diabetes Care; 2014 Apr; 37(4):912-21. PubMed ID: 24103901
    [Abstract] [Full Text] [Related]

  • 5. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial.
    Gadde KM, Allison DB, Ryan DH, Peterson CA, Troupin B, Schwiers ML, Day WW.
    Lancet; 2011 Apr 16; 377(9774):1341-52. PubMed ID: 21481449
    [Abstract] [Full Text] [Related]

  • 6. Phentermine/topiramate for the treatment of obesity.
    Smith SM, Meyer M, Trinkley KE.
    Ann Pharmacother; 2013 Mar 16; 47(3):340-9. PubMed ID: 23482732
    [Abstract] [Full Text] [Related]

  • 7. Changes in cardiovascular risk associated with phentermine and topiramate extended-release in participants with comorbidities and a body mass index ≥27 kg/m(2).
    Davidson MH, Tonstad S, Oparil S, Schwiers M, Day WW, Bowden CH.
    Am J Cardiol; 2013 Apr 15; 111(8):1131-8. PubMed ID: 23375187
    [Abstract] [Full Text] [Related]

  • 8. Cardiometabolic Disease Staging Predicts Effectiveness of Weight-Loss Therapy to Prevent Type 2 Diabetes: Pooled Results From Phase III Clinical Trials Assessing Phentermine/Topiramate Extended Release.
    Guo F, Garvey WT.
    Diabetes Care; 2017 Jul 15; 40(7):856-862. PubMed ID: 28455281
    [Abstract] [Full Text] [Related]

  • 9. A review of the metabolic effects of controlled-release Phentermine/Topiramate.
    Kiortsis DN.
    Hormones (Athens); 2013 Jul 15; 12(4):507-16. PubMed ID: 24457398
    [Abstract] [Full Text] [Related]

  • 10. A randomized, double-blind, placebo-controlled study of an oral, extended-release formulation of phentermine/topiramate for the treatment of obstructive sleep apnea in obese adults.
    Winslow DH, Bowden CH, DiDonato KP, McCullough PA.
    Sleep; 2012 Nov 01; 35(11):1529-39. PubMed ID: 23115402
    [Abstract] [Full Text] [Related]

  • 11. A randomized, double-blind, placebo-controlled, pharmacokinetic and pharmacodynamic study of a fixed-dose combination of phentermine/topiramate in adolescents with obesity.
    Hsia DS, Gosselin NH, Williams J, Farhat N, Marier JF, Shih W, Peterson C, Siegel R.
    Diabetes Obes Metab; 2020 Apr 01; 22(4):480-491. PubMed ID: 31696603
    [Abstract] [Full Text] [Related]

  • 12. Weight loss and metabolic effects of topiramate in overweight and obese type 2 diabetic patients: randomized double-blind placebo-controlled trial.
    Eliasson B, Gudbjörnsdottir S, Cederholm J, Liang Y, Vercruysse F, Smith U.
    Int J Obes (Lond); 2007 Jul 01; 31(7):1140-7. PubMed ID: 17264849
    [Abstract] [Full Text] [Related]

  • 13. Phentermine, topiramate and their combination for the treatment of adiposopathy ('sick fat') and metabolic disease.
    Bays H.
    Expert Rev Cardiovasc Ther; 2010 Dec 01; 8(12):1777-801. PubMed ID: 20707765
    [Abstract] [Full Text] [Related]

  • 14. A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects.
    Wilding J, Van Gaal L, Rissanen A, Vercruysse F, Fitchet M, OBES-002 Study Group.
    Int J Obes Relat Metab Disord; 2004 Nov 01; 28(11):1399-410. PubMed ID: 15486569
    [Abstract] [Full Text] [Related]

  • 15. A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of topiramate controlled release in the treatment of obese type 2 diabetic patients.
    Rosenstock J, Hollander P, Gadde KM, Sun X, Strauss R, Leung A, OBD-202 Study Group.
    Diabetes Care; 2007 Jun 01; 30(6):1480-6. PubMed ID: 17363756
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of topiramate in combination with metformin in the treatment of obese subjects with type 2 diabetes: a randomized, double-blind, placebo-controlled study.
    Toplak H, Hamann A, Moore R, Masson E, Gorska M, Vercruysse F, Sun X, Fitchet M.
    Int J Obes (Lond); 2007 Jan 01; 31(1):138-46. PubMed ID: 16703004
    [Abstract] [Full Text] [Related]

  • 17. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP).
    Allison DB, Gadde KM, Garvey WT, Peterson CA, Schwiers ML, Najarian T, Tam PY, Troupin B, Day WW.
    Obesity (Silver Spring); 2012 Feb 01; 20(2):330-42. PubMed ID: 22051941
    [Abstract] [Full Text] [Related]

  • 18. A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity.
    Bray GA, Hollander P, Klein S, Kushner R, Levy B, Fitchet M, Perry BH.
    Obes Res; 2003 Jun 01; 11(6):722-33. PubMed ID: 12805393
    [Abstract] [Full Text] [Related]

  • 19. Combination phentermine and topiramate extended release in the management of obesity.
    Alfaris N, Minnick AM, Hopkins CM, Berkowitz RI, Wadden TA.
    Expert Opin Pharmacother; 2015 Jun 01; 16(8):1263-74. PubMed ID: 25958964
    [Abstract] [Full Text] [Related]

  • 20. Coadministration of Canagliflozin and Phentermine for Weight Management in Overweight and Obese Individuals Without Diabetes: A Randomized Clinical Trial.
    Hollander P, Bays HE, Rosenstock J, Frustaci ME, Fung A, Vercruysse F, Erondu N.
    Diabetes Care; 2017 May 01; 40(5):632-639. PubMed ID: 28289041
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.